About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic. Content has been reviewed by experts at the CAP, but does not necessarily reflect the official opinion of the College of American Pathologists. Non-CAP material with identified copyright source may only be copied or distributed under a license (permission) from the copyright holder, or under the doctrine of fair use. Version 1.1, rev. 12/31/2013

Emerging Concepts in Therapeutic Guidance for Metastatic Melanoma Short Presentations in Emerging Concepts (SPEC)

Melanoma Leading cause of death from skin disease Discovery of genes that play a key role in oncogenesis –e.g. BRAF, NRAS, MEK, c-KIT Emerging therapies focus on targeting the activated pathways in melanoma

Molecular Subtypes of Melanoma?

BRAF About 50% of nodular melanomas –Acquired mutation –RAS/RAF/MEK pathway is constitutively activated driving proliferation Most common mutation: V600E –Mutation in DNA causes change in protein amino acid sequence: Valine at amino acid 600 to GlutaminE Second common mutation: V600K –Same amino acid – Valine to Lysine

BRAF Inhibitors Vemurafenib (Aug 2011) Dabrafenib (May 2013) Oral inhibitors of BRAF tyrosine kinase Can have dramatic tumor regression –Subject of 3 part series in New York Times, Feb 2010

New York Times – Feb 2010

Phase 3 Trial Results

J Clin Oncol Apr 1;29(10):

BRAF Mutation Analysis Either primary or metastatic tissue –Formalin-fixed paraffin-embedded (FFPE) Performed using PCR –Very good analytic sensitivity - about 1% –Detects the BRAF mutation with less than 5% tumor cells in the tissue. –More sensitive than sequencing Can be significant in samples with low amount of tumor

Resistance to BRAF Inhibitors Resistance develops through alternate pathway activation of NRAS/MEK Therapeutic option for MEK inhibition using trametinib –FDA approval for monotherapy in BRAF mutated tumors –Not approved as a combination treatment. Preliminary results from a clinical trial suggest that use in combination with dabrafenib significantly improved progression-free survival, although the incidence of pyrexia was increased

c-KIT and Melanoma Mucosal or acral melanomas with activating mutations or amplifications in c- KIT may be sensitive to a variety of c-KIT inhibitors Phase II and phase III trials are available for patients with unresectable stage III or stage IV melanoma harboring the c-KIT mutation

c-KIT testing Response to inhibitors is limited to mutations in certain exons –Amplification not associated with response Image from: Lyle M, Long GV. Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma. J Clin Oncol Sep 10;31(26):

Selected Resources Improved survival with vemurafenib in melanoma with BRAF V600E mutation Chapman PB et al, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: June 30, Vemurafenib (Zelboraf ® ) package insert

Additional Free Resource for CAP Members NOTE: please remove this page before presenting. CAP Member Exclusive: CAP Pathology Resource Guides Focused on a specific hot-topic technology, these comprehensive guides highlights current resources, select journal articles, as well as CAP and non-CAP educational opportunities. And don’t miss the “Insights From Early Adopters” section in each guide to gain perspective from pioneering colleagues. AVAILABLE NOW: Molecular Pathology (single gene test, small panel) Genomic Analysis (large panel, exome, genome) Learn more: go to cap.org and type Pathology Resource Guides in the “search” field located at the top of your screen. “Extremely well done, of high practical and educational value.” “An outstanding overview of basic materials, including the technology and links to a number of individuals and centers that can assist.”